670 related articles for article (PubMed ID: 28869439)
1. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.
Chen J; Cao SW; Cai Z; Zheng L; Wang Q
Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439
[TBL] [Abstract][Full Text] [Related]
2. An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients.
Liu YK; Hu BS; Li ZL; He X; Li Y; Lu LG
Hepatol Int; 2016 Jul; 10(4):640-6. PubMed ID: 27115761
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease.
Li YM; Xu SC; Li J; Han KQ; Pi HF; Zheng L; Zuo GH; Huang XB; Li HY; Zhao HZ; Yu ZP; Zhou Z; Liang P
Cell Death Dis; 2013 Oct; 4(10):e831. PubMed ID: 24091674
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma.
Cheng Y; Luo L; Zhang J; Zhou M; Tang Y; He G; Lu Y; Wang Z; Pan M
J Gastrointest Surg; 2019 Dec; 23(12):2354-2361. PubMed ID: 30805878
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma.
Sun YF; Guo W; Xu Y; Shi YH; Gong ZJ; Ji Y; Du M; Zhang X; Hu B; Huang A; Chen GG; Lai PBS; Cao Y; Qiu SJ; Zhou J; Yang XR; Fan J
Clin Cancer Res; 2018 Feb; 24(3):547-559. PubMed ID: 29070526
[No Abstract] [Full Text] [Related]
6. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer.
Liu DG; Xue L; Li J; Yang Q; Peng JZ
Cancer Biomark; 2018; 22(3):417-426. PubMed ID: 29758927
[TBL] [Abstract][Full Text] [Related]
7. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cell Phenotype Indicates Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma.
Ou H; Huang Y; Xiang L; Chen Z; Fang Y; Lin Y; Cui Z; Yu S; Li X; Yang D
Dig Dis Sci; 2018 Sep; 63(9):2373-2380. PubMed ID: 29926241
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma.
Qi LN; Xiang BD; Wu FX; Ye JZ; Zhong JH; Wang YY; Chen YY; Chen ZS; Ma L; Chen J; Gong WF; Han ZG; Lu Y; Shang JJ; Li LQ
Cancer Res; 2018 Aug; 78(16):4731-4744. PubMed ID: 29915159
[TBL] [Abstract][Full Text] [Related]
11. Twist Expression in Circulating Hepatocellular Carcinoma Cells Predicts Metastasis and Prognoses.
Yin LC; Luo ZC; Gao YX; Li Y; Peng Q; Gao Y
Biomed Res Int; 2018; 2018():3789613. PubMed ID: 30046595
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma.
Chen Y; Li S; Li W; Yang R; Zhang X; Ye Y; Yu J; Ye L; Tang W
Sci Rep; 2019 May; 9(1):7084. PubMed ID: 31068623
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
[TBL] [Abstract][Full Text] [Related]
14. Cell-surface major vault protein promotes cancer progression through harboring mesenchymal and intermediate circulating tumor cells in hepatocellular carcinomas.
Lee HM; Joh JW; Seo SR; Kim WT; Kim MK; Choi HS; Kim SY; Jang YJ; Sinn DH; Choi GS; Kim JM; Kwon CHD; Chang HJ; Kim DS; Ryu CJ
Sci Rep; 2017 Oct; 7(1):13201. PubMed ID: 29038587
[TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma.
Yang X; Ni H; Lu Z; Zhang J; Zhang Q; Ning S; Qi L; Xiang B
BMC Cancer; 2023 Jan; 23(1):10. PubMed ID: 36600214
[TBL] [Abstract][Full Text] [Related]
20. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
